DELAFIELD, Wis. (Stockpickr) -- Professional traders running mutual funds and hedge funds don't just look at a stock's price moves; they also track big changes in volume activity. Often when above-average volume moves into an equity, it precedes a large spike in volatility.
>>5 Stocks Poised for Breakouts
Major moves in volume can signal unusual activity, such as insider buying or selling -- or buying or selling by "superinvestors."
Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst. These types of traders like to get in well before a large spike, so it's always a smart move to monitor unusual volume. That said, remember to combine trend and price action with unusual volume. Put them all together to help you decipher the next big trend for any stock.
>>5 Huge Stocks to Trade for Huge Gains
With that in mind, let's take a look at several stocks rising on unusual volume recently.
Top Construction Companies To Own In Right Now: Strategic Hotels and Resorts Inc (BEE)
Strategic Hotels & Resorts, Inc. (SHR), incorporated on January 27, 2004, operates as a self-administered and self-managed real estate investment trust (REIT). As of December 31, 2012, the Company�� portfolio included 18 full-service hotel interests located in urban and resort markets in the United States; Punta Mita, Nayarit, Mexico; Hamburg, Germany, and London, England. SHR conducts its operations through its direct and indirect subsidiaries, including its operating partnership, Strategic Hotel Funding, L.L.C. (SH Funding), which holds all of the Company�� assets. SHR is the sole managing member of SH Funding and held approximately 99% of its membership units as of February 27, 2013. SHR manages all business aspects of SH Funding, including the sale and purchase of hotels, the investment in these hotels and the financing of SH Funding and its assets. In September 2012, it acquired the JW Marriott Essex House Hotel in New York City. In October 2013, the Company announced that it has sold the Lakeshore Athletic Club property adjacent to the Fairmont Chicago hotel.
As of December 31, 2012, SH Funding owned interests in or leased 18 hotels, which included Fairmont Chicago, Fairmont Scottsdale Princess, Four Seasons Jackson Hole, Four Seasons Punta Mita Resort, Four Seasons Silicon Valley, Four Seasons Washington, D.C., Hotel del Coronado, Hyatt Regency La Jolla, InterContinental Chicago, InterContinental Miami, JW Marriott Essex House Hotel, Loews Santa Monica Beach Hotel, Marriott Hamburg, Marriott Lincolnshire Resort, Marriott London Grosvenor Square, Ritz-Carlton Half Moon Bay, Ritz-Carlton Laguna Niguel and Westin St. Francis.
The Hotel del Coronado is operated by a specialty management company, KSL Resorts. As of February 27, 2013, the Company wholly owned or leased 14 hotels, had a 53.5% and 51.0% interest in an affiliate that owned a hotel where it asset managed such hotel, and had 50.0% and 36.4% interests in, and acted as asset manager for, two affiliates that eac! h owned one hotel, and owned land held for development, including 20.5 acres of oceanfront land adjacent to its Four Seasons Punta Mita Resort, Nayarit, Mexico and 60 acres of oceanfront land near the Four Seasons Punta Mita Resort; a 20,000 square-foot parcel of land on the ocean in Santa Monica, California adjacent to its Loews Santa Monica Beach Hotel entitled for development and residential units; a 50% interest in an affiliate that owned 10 acres of land adjacent to the Fairmont Scottsdale Princess hotel, and a 31% interest in an affiliate with two parties that was developing the fractional ownership program known as the Four Seasons Residence Club Punta Mita.
Advisors' Opinion:- [By James E. Brumley]
In a perfect world, an investor could simply look at a company's history and its plausible earnings forecasts, and jump in (or out) knowing the stock's current price basically made sense with respect to past and future performance. We don't live or trade in a perfect world though. In the world we're actually in right now, most stocks, sectors, and industries have run up far beyond a justifiable value... perhaps except for hotel and lodging REIT stocks Host Hotels and Resorts Inc. (NYSE:HST), Strategic Hotels and Resorts Inc. (NYSE:BEE), and Pebblebrook Hotel Trust (NYSE:PEB).
- [By Rich Duprey]
Luxury hotel and resort operator�Strategic Hotels & Resorts� (NYSE: BEE ) �announced yesterday�its second-quarter dividend on three series of cumulative redeemable preferred stock.
Top Rising Stocks To Own For 2014: Digi International Inc.(DGII)
Digi International Inc. engages in the provision of machine to machine networking products and solutions to connect, monitor, and control of local or remote physical assets by electronic means. It offers a range of embedded products, including modules, single board computers, chips, satellite communication devices, and software and development tools; and non embedded products comprising cellular products, serial servers, console servers, universal serial bus connected products, serial cards, and wireless communication adaptors. The company also provides wireless product design and development services to provide wireless networking products. In addition, it offers iDigi, a cloud-based Internet platform to connect enterprise applications to remote electronic devices. The company sells its products through a network of distributors, systems integrators, and value added resellers for a range of businesses and institutions, as well as to original equipment manufacturers primar ily in North America, Europe, the Middle East, Africa, Asia, and Latin America. It has strategic alliances with VMware, Ember, Freescale, Qualcomm, Ericsson, Itron, AT&T, Sprint, Verizon, Bell Mobility, and Rogers. The company was founded in 1985 and is headquartered in Minnetonka, Minnesota.
Advisors' Opinion:- [By John Kell]
Digi International Inc.'s(DGII) fiscal first quarter earnings fell, as high costs masked a slight rise in revenue. The wireless-product provider’s results were well-below the company’s previous guidance. Shares slumped 9.9% to $10.89 premarket.
Top Rising Stocks To Own For 2014: Ophthotech Corp (OPHT)
Ophthotech Corporation, incorporated on January 05, 2007, is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye. The Company�� advanced product candidate is Fovista, which the Company is developing for use in combination with anti-VEGF drugs that represent the current standard of care for the treatment of wet age-related macular degeneration (wet AMD). Wet AMD is a serious disease of the central portion of the retina, known as the macula, which is responsible for detailed central vision and color perception. It is characterized by abnormal new blood vessel formation and growth, referred to as neovascularization, which results in blood vessel leakage, retinal distortion and scar formation. If untreated, the progressive retinal damage results in rapid, irreversible and severe vision loss. Wet AMD is the cause of blindness in patients over the age of 55 in the United States and the European Union.
The anti-VEGF market for the treatment of wet AMD consists predominantly of two drugs that are approved for marketing and primarily prescribed for the treatment of wet AMD, Lucentis and Eylea, and off-label use of the cancer therapy Avastin. The use of anti-VEGF drugs has significantly improved visual outcomes for patients with wet AMD who have been treated with these drugs as compared to untreated patients.
Advisors' Opinion:- [By Todd Campbell]
That leads me to Medivation (NASDAQ: MDVN ) , Ophthotech (NASDAQ: OPHT ) , and Portola (NASDAQ: PTLA ) , three companies with important therapies that may very well be destined to become top sellers.
- [By John Udovich]
If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:
- [By John Udovich]
The biotech sector has been pretty exciting this year�with small cap biotech stocks Prana Biotechnology Limited (NASDAQ: PRAN) and TNI BioTech (OTCMKTS: TNIB) having recently produced noteworthy news for investors�while Acceleron Pharma, Inc (NASDAQ: XLRN), Ophthotech (NASDAQ: OPHT) and BIND Therapeutics (NASDAQ: BIND) have just�set term sheets for their upcoming IPOs. Just consider all of the following recent news:
Top Rising Stocks To Own For 2014: Catalyst Pharmaceutical Partners Inc.(CPRX)
Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. It is evaluating its lead product candidate, CPP-109, a GABA aminotransferase inhibitor candidate, which is under Phase II(b) clinical trial for the treatment of cocaine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. The company is also developing CPP-115, a GABA aminotransferase inhibitor for various indications, including drug addiction, epilepsy, and for other selected central nervous disease indications. It has license agreements with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions, and obsessive-compulsive disorders; and with Northwestern University to commercialize GABA aminotransferase inhibitors worldwide, as well as a definitive clinical trial agreement with the National Institute on Drug Abuse to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109 for the treatment of cocaine addiction. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Advisors' Opinion:- [By Roberto Pedone]
Catalyst Pharmaceutical Partners (CPRX) is focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. This stock closed flat to $1.87 in Tuesday's trading session.
Tuesday's Range: $1.78-$1.98
52-Week Range: $0.41-$3.65
Tuesday's Volume: 1.62 million
Three-Month Average Volume: 2.20 millionFrom a technical perspective, CPRX closed off its intraday low of $1.78 to $1.87 with lighter-than-average volume. This stock has been uptrending for the last few weeks, with shares moving higher from its low of $1.29 to its recent high of $2.07. During that move, shares of CPRX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CPRX within range of triggering a near-term breakout trade. That trade will hit if CPRX manages to take out some near-term overhead resistance levels at $2.07 to its 50-day moving average of $2.16 with high volume.
Traders should now look for long-biased trades in CPRX as long as it's trending above some near-term support at $1.63 and then once it sustains a move or close above those breakout levels with volume that's near or above 2.20 million shares. If that breakout hits soon, then CPRX will set up to re-test or possibly take out its next major overhead resistance levels at $2.87 to $3. Any high-volume move above those levels will then give CPRX a chance to re-test its 52-week high at $3.65.
- [By Paul Ausick]
Stocks on the move: Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) is up about 40% at $1.98 after its firdapse drug treatment for certain kinds of muscle weakness was designated a breakthrough therapy by the FDA. Food maker Dean Foods Inc. (NYSE: DF) held a 1-for-2 reverse stock split this morning and the shares are up about 95%, as might be expected.
- [By Roberto Pedone]
One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Catalyst Pharmaceutical Partners (CPRX), which is focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. This stock has been on fire so far in 2013, with shares up a whopping 364%.
If you take a look at the chart for Catalyst Pharmaceutical Partners, you'll notice that this stock has been uptrending strong for the last month, with shares soaring higher from its low of $1.29 to its intraday high of $2.09 a share. During that uptrend, shares of CPRX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed share of CPRX within range of triggering a big breakout trade.
Traders should now look for long-biased trades in CPRX if it manages to break out above its 50-day moving average of $2.11 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 2.21 million shares. If that breakout triggers soon, then CPRX will set up to re-test or possibly take out its next major overhead resistance levels at $2.87 to $3 a share. Any high-volume move above those levels will then give CPRX a chance to re-test its 52-week high at $3.65 a share.
Traders can look to buy CPRX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $1.65 to $1.63 a share. One can also buy CPRX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top Rising Stocks To Own For 2014: Bunge Limited(BG)
Bunge Limited, through its subsidiaries, engages in the agriculture and food businesses worldwide. Its Agribusiness segment is involved in purchasing, storing, transporting, processing, and selling agricultural commodities and commodity products, such as oilseeds and grains, primarily comprising soybeans, rapeseed or canola, sunflower seed, wheat, and corn. This segment serves animal feed manufacturers, wheat and corn millers, third party edible oil processing companies, and other oilseed processors, as well as livestock, poultry, and aquaculture producers. The company?s Sugar and Bioenergy segment produces and sells sugar and ethanol; generates electricity from burning sugarcane bagasse; and trades and merchandises sugar. As of December 31, 2011, this segment had a total installed capacity of approximately 144 megawatts; and sugarcane plantations of approximately 183,000 hectares under cultivation. Its Edible Oil Products segment offers packaged vegetable, including pack aged and bulk oils, shortenings, margarines, mayonnaise, and other products to baked goods companies, snack food producers, restaurant chains, foodservice distributors, and other food manufacturers. The company?s Milling Products segment produces and sells various wheat flours and bakery mixes; corn-based products; corn milling products primarily comprising dry milled corn meals, flours, and grits, as well as soy-fortified corn meal and corn-soy blend; and packaged milled rice. This segment serves industrial, bakery, and foodservice companies; and companies in food processing sector. Its Fertilizer segment produces, blends, and distributes nitrogen, phosphate, and potash formulations used for the cultivation of soybeans, corn, sugarcane, cotton, wheat, and coffee. This segment also produces single super phosphate; and ammonia, urea, and liquid fertilizers for the agriculture industry. Bunge Limited was founded in 1818 and is headquartered in White Plains, New York.
Advisors' Opinion:- [By Maxx Chatsko]
Investors will be on the lookout for further, perhaps larger, customer announcements in the coming quarters. Just remember that there is plenty of time between now and mid-2015. Until then, there should be no worries from the guidance and commercialization aid Solazyme will receive from agri-giants Bunge (NYSE: BG ) and Archer Daniels Midland (NYSE: ADM ) .
- [By Ben Levisohn]
Korn and Teller downgraded Mosaic to Equal Weight from Overweight, but expect CF Industries (CF), Agrium and Bunge (BG) to do well in 2014, despite no obvious catalysts.
- [By David Sterman]
He subsequently closed that position with a nice profit, and he should now check out rival Bunge (NYSE: BG), which in my view, holds better value. (I'll have more to say about Bunge in a separate column in coming weeks).
Top Rising Stocks To Own For 2014: Polaris Industries Inc. (PII)
Polaris Industries Inc. designs, engineers, and manufactures off-road vehicles. It offers all terrain vehicles and side-by-side vehicles for recreational and utility use; snowmobiles; and on-road vehicles, including motorcycles and low emission vehicles. The company also provides replacement parts and accessories, including winches, bumper/brushguards, plows, racks, mowers, tires, pull-behinds, cabs, cargo box accessories, tracks, and oil for off-road vehicles; covers, traction products, reverse kits, electric starters, tracks, bags, windshields, oil, and lubricants for snowmobiles; and saddle bags, handlebars, backrests, exhaust, windshields, seats, oil, and various chrome accessories for motorcycles. Polaris Industries sells its products through dealers and distributors primarily under the RANGER, RANGER RZR, RANGER Crew, Victory Vision, Victory Cross Roads, Polaris RUSH, and Cross Country trade marks. In addition, it markets helmets, jackets, bibs and pants, leathers, a nd hats through dealers and distributors, as well as online under the Polaris brand name. The company principally operates in the United States and Canada. Polaris Industries Inc. was founded in 1987 and is headquartered in Medina, Minnesota.
Advisors' Opinion:- [By Jonas Elmerraji]
Shareholders in Polaris Industries (PII) are having a stellar year in 2013; shares of the $9 billion ATV manufacturer are up more than 55% since the calendar flipped over to January. But even if you missed the move, you shouldn't ignore this stock. PII looks like it's still got higher ground ahead of it.
That's because Polaris is currently forming an ascending triangle pattern, a bullish price setup that's formed by a horizontal resistance level above shares at $137 and uptrending support to the downside. Basically, as PII bounces in between those two technical levels, it's getting squeezed closer and closer to a breakout above $137. When that happens, we've got a buy signal in shares.
Berkshire is currently forming a descending triangle pattern, the bearish opposite of the ascending triangle in PII. The descending triangle is formed by downtrending resistance pushing down from above shares and horizontal support to the downside, in this case at $111. A breakdown through $111 is Berkshire's sell signal.
A parabolic drop in relative strength since June indicates that Berkshire has been woefully underperforming the S&P 500 in recent months -- you can see it from the stock's inability to make new highs in November. Buyers look anemic here, but failure to catch a bid at $111 is the start of something bigger.
Don't sell unless Warren Buffett's baby unless shares fall through that price floor.
- [By Rich Smith]
ATV, snowmobile, and motorcycle maker Polaris Industries (NYSE: PII ) has acquired French on-road "quadricycle" vehicle manufacturer Aixam Mega S.A.S., Polaris announced Thursday.
- [By Rich Duprey]
Unfortunately, product recalls are a fact of life these days for manufacturers, and bike makers from Honda to�Suzuki to Triumph have all had to recall motorcycles. Last year, BMW recalled over 2,000 bikes because of a foaming brake fluid problem that could inhibit braking. Triumph recalled some 12,000 bikes because of a stalling problem. And Polaris Industries (NYSE: PII ) recalled 6,600 Victory motorcycles for throttle cable problems. In 2011, Honda had to recall 126,000 bikes made between 2001 and 2010, as well as certain models of its 2012 Goldwing because of a braking issue.
- [By Faisal Humayun]
Polaris Industries (PII), which designs, engineers, manufactures, and markets off-road vehicles, snowmobiles, motorcycles, and small vehicles in the United States, Canada, and Western Europe is a strong buy even at current levels. This article discusses the positives related to the company making it a good stock to own for long-term.
No comments:
Post a Comment